The DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index; 43 of the 90 sources its claims cite were checked for support.
Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol
Open accessAbstract
Background: Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased attention over the past decades. Evidence-based approaches to prevent PGD are currently scarce, and not always effective. This paper introduces a protocol for a clinical trial exploring the effectiveness of a Meaning Reconstruction psychotherapy approach (MR) assisted with ayahuasca, a traditional indigenous medicine. Method: The outlined protocol is a three-arm, non-randomized controlled trial focused on reducing normal and pathological grief symptoms, comparing the effectiveness of Ayahuasca-assisted MR therapy (A-MR), MR therapy alone (MR) and No Treatment (NT). At least 69 people who lost a first-degree relative during the prior year, and with a Texas Revised Inventory of Grief score up 39 (TRIG ≥ 40), will participate in the trial. Participants will be allocated to an A-MR (n ≥ 23), MR (n ≥ 23) or NT (n ≥ 23) group. Those from the A-MR and MR therapy groups will undergo a therapeutic process involving 9 sessions of online psychotherapy. In addition, the A-MR condition involves 2 group sessions of ayahuasca. The primary outcomes will be normal and pathological grief severity as measured by the TRIG and Traumatic Grief Inventory Self-Report (TGI-SR), administered at baseline, post-treatment, and 3-month follow up. Measures of quality of life, post-traumatic growth, meaning-made, psychological flexibility, and self-belief consistency will be also included. In addition, subjective effects of ayahuasca and acceptance-avoidance promoting effects will be assessed following ayahuasca administration. Finally, we will analyze the potential mediating effect of meaning-made, psychological flexibility and self-belief consistency in grief symptoms (as measured by the TRIG and TGI). Discussion: This trial is the first to empirically examinate the potential of psychedelic-assisted psychotherapy for grief, as well as the potential processes of change that may account for it. Clinical trial registration: https://clinicaltrials.gov, identifier NCT06150859. Copyright © 2025 Sabucedo, Andión, Neimeyer, Soto-Angona, Javkin, Haro, Farré and González.
Overview
CoChat Summary
## TL;DR
This paper is a non-randomized clinical trial protocol testing whether ayahuasca-assisted Meaning Reconstruction therapy (A-MR) reduces grief symptoms better than Meaning Reconstruction therapy alone (MR) or no treatment (NT) in bereaved adults. It also plans to examine whether changes in meaning-made, psychological flexibility, and self-belief consistency mediate any effects.
## Key findings
- Not stated in the paper.
- The protocol plans a three-arm, non-randomized controlled trial with at least 69 participants and 84 to be recruited to allow for 20% dropout.
- Participants will be allocated to A-MR (n ≥ 23), MR (n ≥ 23), or NT (n ≥ 23).
- The primary outcomes are grief severity measured by TRIG and TGI-SR, assessed at baseline, post-treatment, and 3-month follow-up; secondary outcomes include quality of life and post-traumatic growth.
## Methods
- Design: Three-arm, non-randomized controlled trial protocol comparing A-MR, MR, and NT; participants are sequentially allocated.
- Sample/data: English- and Spanish-speaking adults aged 18–65 who lost a first-degree relative within the past 12 months and have TRIG ≥ 40; exclusions include psychosis history, hypertension, substance use disorder (except nicotine), and concurrent grief treatment.
- Analysis: Descriptive statistics, baseline group comparisons, repeated-measures ANOVA and/or linear mixed models, with Bonferroni corrections; mediation analyses for meaning-made, psychological flexibility, and self-belief consistency using lavaan.
## Limitations
- The paper states that sequential allocation may bias outcomes.
- It states that self-referral recruitment via psychedelic research/education institutions may limit generalizability to the general population.
- It states that using a plant concoction makes it difficult to determine which alkaloids and active compounds drive outcomes.
- Evident from the text: this is a protocol, so it reports planned analyses and hypothesized outcomes rather than trial results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Valid · 1 Not valid · 17 Not checked · 5 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, elevated peripheral Brain-Derived Neurotropic Factor (BDNF) levels have been observed in healthy volunteers and clinically depressed patients two days following the ayahuasca administration, correlating with clinical improvement in those who were diagnosed with major depression (40).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Supportedcites [40] de Almeida, 2019, Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial, Front Psychol source
The Abstract and Discussion report higher serum BDNF 48 hours after ayahuasca than after placebo in both healthy controls and patients with treatment-resistant depression. The Discussion also reports that, among patients given ayahuasca, higher BDNF at that time was significantly correlated with fewer depressive symptoms. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Looking beyond the neurobiological evidence, several studies indicate that the therapeutic effect is experience-dependent (50, 51).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Not checked — no full text of the sourcecites [50] Brouwer, 2021, Pivotal mental states, J Psychopharmacology doi:10.1177/026988112095963
- Supportedcites [51] Ko, 2022, Psychedelics, mystical experience, and therapeutic efficacy: A systematic review, Front Psychiatry source
The Discussion reports an association between mystical experience and therapeutic outcome in most of the 12 studies reviewed, including significant correlations in nine studies and evidence of mediation in several. It concludes that the presence and intensity of the experience contribute to therapeutic efficacy, supporting the citing sentence's hedged claim. (LLM, conf=0.89)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A window for neuroplastic changes would appear to open a few hours after administration, lasting from a few days to a month (44).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Partly supportedcites [44] Calder, 2023, Towards an understanding of psychedelic-induced neuroplasticity, Neuropsychopharmacology sourceExperimental — accuracy not yet measured
The Conclusions say the neuroplasticity window appears to open within a few hours and may last a few days; changes formed during it may survive for at least a month. The duration section reports elevated BDNF two days after ayahuasca, but does not establish that ayahuasca specifically opens a window lasting up to a month. The claim conflates the window’s duration with the persistence of changes formed during it. (LLM, conf=0.89)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recent studies have shown that psychedelics reopen a critical period to induce metaplasticity, which dynamically regulates the potential for synaptic plasticity (46, 47).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Supportedcites [46] Nardou, 2023, Psychedelics reopen the social reward learning critical period, Nature source
The Abstract reports that psychedelics reopen the social reward learning critical period in mice, alongside metaplastic restoration of oxytocin-mediated plasticity. The “Metaplasticity, not hyperplasticity” section defines metaplasticity as dynamic regulation of the extent to which synaptic plasticity can be induced and reports evidence that psychedelics induce it. Page numbers are not provided in the supplied passages. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [47] Nardou, 2019, Oxytocin-dependent reopening of a social reward learning critical period with MDMA, Nature source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“in vitro, animal and human studies have demonstrated how harmine, tetrahydroharmine, harmaline (all three present in B. caapi) and dimethyltryptamine (present in P. viridis) stimulate adult neurogenesis and neuroplasticity, similarly to other serotoninergic psychedelic substances (40–43).”
§ Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol > Introduction > Psychedelic-assisted grief therapy
What the sources say
- Partly supportedcites [40] de Almeida, 2019, Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial, Front Psychol sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that in vitro studies suggest neuronal proliferation, migration and differentiation from ayahuasca β-carbolines, and that harmine may increase hippocampal BDNF in rodents. It discusses neuroplasticity findings for 5-methoxy-N,N-dimethyltryptamine, which is distinct from the N,N-dimethyltryptamine named in the claim. The paper does not establish that each of the four named compounds stimulates adult neurogenesis and neuroplasticity in humans; its human trial measured serum BDNF instead. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [41] Kelley, 2022, Pharmahuasca and DMT rescue ROS production and differentially expressed genes observed after predator and psychosocial stress: Relevance to human PTSD, ACS Chem Neurosci source
- Partly supportedcites [42] Morales-García, 2017, The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro, Sci Rep sourceExperimental — accuracy not yet measured
The Discussion reports that harmine, tetrahydroharmine and harmaline stimulated adult neurogenesis in an in vitro model using cells from adult mice. It also says DMT was not tested and that in vivo neurogenesis remains for future study. The source therefore does not demonstrate the claimed effects for DMT, in animals or humans, or a comparable effect to other serotonergic psychedelics. (LLM, conf=0.90)
- Partly supportedcites [43] Morales-García, 2020, N, N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo, Trans Psychiatry sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that DMT promotes adult neurogenesis in vitro and in vivo and that earlier in vitro work found neurogenic effects of β-carbolines from B. caapi. It does not report human studies demonstrating that these compounds stimulate neurogenesis or neuroplasticity; the human studies it mentions concern ayahuasca’s antidepressant activity. It also identifies sigma-1 receptor activation, rather than a demonstrated similarity to other serotonergic psychedelics, as the mechanism of DMT’s neurogenic effect. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
13 more claims · 5 with their cited sources checked
Create a free account to see all 51 claims and to verify the 2 references still open.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 17
Citations
Cites
lavaan : An R Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138 · cited 1×
“The following R packages will be used for data exploration, description, and preprocessing if necessary: tidyverse (80), car (81), moments version 0.14.1 (82), and nortest version 1.0-4 (83).”
InfluentialDevelopment of the World Health Organization WHOQOL-BREF Quality of Life Assessment
THE WHOQOL GROUP (1998) · Psychological Medicine · doi:10.1017/s0033291798006667 · Cited by 7,933 · cited 1×
“This questionnaire is a shorter version of the original WHOQOL-100 (67).”
TARGET ARTICLE: "Posttraumatic Growth: Conceptual Foundations and Empirical Evidence"
Tedeschi, R. G., & Calhoun, L. G. (2004) · Psychological Inquiry · doi:10.1207/s15327965pli1501_01 · Cited by 7,154 · cited 1×
“This questionnaire measures the degree of positive change experienced in the aftermath of a traumatic event (63, 64).”
Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018486.91360.00 · Cited by 4,686
International Statistical Classification of Diseases and Related Health Problems
(2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_3055 · Cited by 4,151
Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.007 · Cited by 3,950
THE DUAL PROCESS MODEL OF COPING WITH BEREAVEMENT: RATIONALE AND DESCRIPTION
Schut, M. S. (1999) · Death Studies · doi:10.1080/074811899201046 · Cited by 2,560
Self-concept clarity: Measurement, personality correlates and cultural boundaries
Campbell, J. D., Trapnell, P. D., Heine, S. J., Katz, I. M., Lavallee, L. F., & Lehman, D. R. (1996) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.70.1.141 · Cited by 2,088 · cited 1×
“This 12-item scale measure the clarity and cohesiveness of the person ’ s self-concept (76).”
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · cited 1×
“This design is based on the contemporary structure of PAP, which typically involves a three-stage framework encompassing preparation, facilitation, and integration (104).”
Research works printed but not linked: 10
- 2022, Diagnostic and Statistical Manual of Mental Disorders: DSM-5-TR
- Neimeyer, 2023, “Grief Therapy as a Quest for Meaning”. In: Steffen EM, Milman E, Neimeyer RA, editors, The Handbook of Grief Therapies.
- McKenna, 1999, Ayahuasca: An ethnopharmacologic history, 187
- Faschingbauer, 1981, The Texas Revised Inventory of Grief manual
- Faschingbauer, 1987, The Texas revised inventory of grief
- Dittrich, 2010, 5D-ASC: Questionnaire for the assessment of altered states of consciousness: A short introduction
- 2023, R: A Language and Environment for Statistical Computing
- Fox, 2019, An R companion to applied regression
- Hedtke, 2016, Introducing the deceased
- Lundgren, 2018, Values choice and clarification
Cited by
Grief as a Quest for Meaning: Review of a Research Program
Neimeyer, R. A. (2026) · Journal of Constructivist Psychology · doi:10.1080/10720537.2026.2688401 · Cited by 7
Self-citationSoto-Angona, Ó., Andión, Ó., Sabucedo, P., Neimeyer, R. A., Haro, J. M., Javkin, J., Farré, M., & González, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-13251-5 · Cited by 5
Self-citationRegistered Clinical Trials of Ayahuasca and DMT : A Scoping Review
Stojanovic, T., Nilsson, K. W., Fredriksson, R., Schiöth, H. B., & Moulin, T. C. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70311 · Cited by 3
Psychedelic-assisted grief therapy: a mixed-method case study
Sabucedo, P., Evans, C., Nicolson, D., Farré, M., & González, D. (2024) · Mortality · doi:10.1080/13576275.2024.2434456 · Cited by 2
“The 9-session MRT protocol (see Sabucedo et al., 2024) can be subdivided into three distinct treatment phases, each focused on a different mechanism of change according to the model.”
Self-citationTorales, J. C., O’Higgins, M., Barrios, I., Caycho-Rodríguez, T., Castaldelli-Maia, J. M., & Ventriglio, A. (2026) · Industrial Psychiatry Journal · doi:10.4103/ipj.ipj_489_25
Metadata
- Authors
- Sabucedo, P., Andión, O., Neimeyer, R. A., Soto-Angona, O., Javkin, J., Haro, J. M., Farré, M., & González, D.
- Affiliations
- University of Liverpool (GB)
- Sociedad española de medicina psicodélica (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Universidad Isabel I (ES)
- Corresponding author
- González, Débora
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2025-01-07
- Volume
- 15
- Pages
- 1484736-1484736
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC11747804
- OpenAlex
- W4406127324
- Cited by
- 6
- References
- 103
- Citations by year
- 2026: 4 · 2025: 1
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Update notices
- corrigendum (2025-04-01)
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Grief, Bereavement, and Mental Health
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- prolonged grief disorder, ayahuasca, psychedelic-assisted psychotherapy, grief, online therapy, psychological flexibility, posttraumatic growth, traumatic grief
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol. https://app.cochat.ai/papers/10.3389/fpsyt.2024.1484736
- The paper
- Sabucedo, P., Andión, O., Neimeyer, R. A., Soto-Angona, O., Javkin, J., Haro, J. M., Farré, M., & González, D. (2025). Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1484736
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
